Neoadjuvant Bevacizumab in Newly Diagnosed, Surgically Resectable Glioblastoma: A Systematic Review and Meta-Analysis of Survival and Functional Outcomes

Authors:

Farbod Tabasi Kakhki[1], Fatemeh Sadat Hosseini Khajouei[2], Aysan Valinejad qanati, MD, MPH[3], Maryam Babazadeh[4], Roozbeh Tavanaei[1], Melika Hajimohammadebrahim-Ketabforoush, PhD[1], Sayeh Oveisi[5], Saeed Oraee-Yazdani[1], Alireza Zali, MD[6], Farzan Fahim, MD, MPH, HMBA[1]

1: Functional Neurosurgery Research Center, Research Institute of Functional Neurosurgery, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2: Medical student, Student Research Committee, Arak University of Medical Sciences, Arak, Iran

3: Center for Orthopedic Trans-Disciplinary Applied Research, Tehran University of Medical Sciences, Tehran, Iran

4: Student research committee, Tabriz University of Medical Sciences, Tabriz, Iran

5: Microbiology student, at Tehran's Azad University of Medical Science, Tehran, Iran

6: professor of neurosurgery, functional neurosurgery of research center, Shohada-E-Tajrish hospital, Shahid Beheshti University of Medical Science, stereotactic fellowship, Tehran, Iran

Corresponding author:

Farzan Fahim, MD, MPH, HMBA

Email: Farzn.fahim@gmail.com

Abstract:

Background:

Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with limited survival despite maximal safe resection and chemoradiotherapy. Neoadjuvant bevacizumab (BEV) has been proposed to reduce peritumoral edema, improve functional status, and potentially enhance progression-free survival (PFS). However, its survival benefit in newly diagnosed, surgically resectable GBM remains unclear.

Objective:

To systematically review and quantitatively synthesize the evidence on neoadjuvant BEV in adult patients with newly diagnosed, resectable GBM, focusing on survival and functional outcomes.

Methods:

Following PROSPERO registration (CRD420251078761), we searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library up to July 20, 2025, without language restrictions. Eligible randomized trials, non-randomized trials, and cohort studies compared neoadjuvant BEV (alone or with other therapies) to standard care without BEV. Primary outcomes were overall survival (OS) and PFS; secondary outcomes included Karnofsky Performance Status (KPS), steroid use, radiological response, and biomarkers. Data were pooled using a random-effects model.

Results:

Thirteen studies (2 RCTs, 7 non-randomized trials, 4 cohorts) met the inclusion criteria; four (n=751) were eligible for meta-analysis. Pooled HR for OS was 0.72 (95% CI: 0.42–1.25, p=0.246) and for PFS was 0.72 (95% CI: 0.42–1.22, p=0.220), both with low heterogeneity (I^2=0%). Functional outcomes suggested improved KPS and reduced steroid dependence, but certainty was low. Biomarker and radiological findings were inconsistent.

Conclusions:

Neoadjuvant BEV in resectable GBM does not significantly improve OS or PFS but may offer symptomatic and functional benefits. Current evidence is limited by small sample sizes, heterogeneous protocols, and low methodological quality. Well-designed multicenter RCTs are warranted.

Keywords: Glioblastoma; Neoadjuvant Therapy; Bevacizumab; Preoperative Care; Karnofsky Performance Status; Systematic Review.

Introduction

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, accounting for approximately 50–60% of all malignant gliomas, with an annual incidence of 3–4 cases per 100,000 population and a median overall survival (OS) of only 14–16 months despite maximal treatment (1-3).Standard-of-care therapy for newly diagnosed, surgically resectable GBM includes maximal safe resection followed by concurrent radiotherapy with temozolomide (TMZ) and adjuvant TMZ (the Stupp protocol)(4). However, even with optimal resection, postoperative neurological deterioration, persistent peritumoral edema, and seizure or steroid dependence remain common, adversely affecting both quality of life and functional independence (5, 6).

Bevacizumab (BEV), a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), has demonstrated potent anti-angiogenic effects, reduction of peritumoral vasogenic edema, and rapid radiologic responses in GBM (7-9). While its FDA approval is restricted to recurrent GBM based on radiographic response rates, multiple investigations have explored BEV in the adjuvant and recurrent settings, showing consistent improvements in

progression-free survival (PFS) but no definitive OS benefit(10-12). In the neoadjuvant context (administration before surgical resection), BEV offers several theoretical advantages: improved tumor oxygenation, decreased vascular permeability, reduced intracranial pressure, and potentially safer, more extensive resections due to diminished edema (13-15).

Despite these potential benefits, evidence for neoadjuvant BEV in newly diagnosed, resectable GBM remains sparse and methodologically heterogeneous. Existing studies vary in dosing schedule (single versus multiple preoperative doses), concurrent therapies (BEV with or without TMZ and/or preoperative radiotherapy), and the interval between BEV administration and surgery (16, 17).Furthermore, although early reports suggest improvements in neurological and functional measures (particularly Karnofsky Performance Status (KPS) preservation, cognitive function, and steroid discontinuation),these outcomes have rarely been synthesized systematically or meta-analyzed(13, 18, 19). Given that maintaining KPS ≥70 is one of the strongest independent prognostic factors for survival in GBM(20), the functional impact of BEV may be as clinically relevant as its survival effects.

There is currently no comprehensive systematic review and meta-analysis exclusively evaluating neoadjuvant BEV in newly diagnosed, surgically resectable GBM, integrating both survival endpoints (OS, PFS) and functional/neurological outcomes. In addition, no prior synthesis has combined clinical results with imaging, histopathological, and biomarker findings to provide a multi-dimensional picture of BEV's perioperative effects. Addressing this knowledge gap is timely, given the emerging interest in perioperative systemic therapies in neuro-oncology and ongoing debates regarding cost-effectiveness and patient selection based on predictive biomarkers (21-23).

Therefore, the present study systematically reviews and quantitatively synthesizes the available evidence from clinical trials and cohort studies on neoadjuvant BEV in newly diagnosed GBM patients eligible for surgical resection, with a dual focus on (1) survival outcomes (OS, PFS) and (2) functional and radiological endpoints, while also summarizing biological correlates where available. This approach aims to clarify the potential role of neoadjuvant BEV in contemporary GBM management and to identify gaps requiring future targeted research.

Methodology

This systematic review and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) to ensure methodological transparency and to avoid duplication. The protocol is publicly available in PROSPERO 2025 (CRD420251078761). The most recent version (Version 3.0, published 23 August 2025) includes amendments to the types of studies considered eligible for inclusion and introduces additional restrictions to the

eligibility criteria.

Search Strategy

A comprehensive set of keywords was used to search for and collect relevant studies in PubMed, Scopus, Web of Science, Embase, and the Cochrane Library. No limitation of date and language was applied. The keywords included: "bevacizumab", "chemotherapy, adjuvant", "radiotherapy, adjuvant", "adjuvants, pharmaceutic", "neoadjuvant therapy", "radiation", "temozolomide", "glioblastoma", "glioblastoma multiforme", "GBM", "grade IV glioma", "high-grade glioma", and "Avastin". Only articles published (including online-first publications) inception to 20 July 2025 were considered.

This is pubmed syntax: (((radiation[Text Word] OR temozolomide[Text Word] OR adjuvant chemotherapy[Text Word] OR adjuvant radiotherapy[Text Word] OR pharmaceutic adjuvants[Text Word] OR neoadjuvant therapy[Text Word])) AND (glioblastoma[Text Word] OR "glioblastoma multiforme"[Text Word] OR GBM[Text Word] OR "grade IV glioma"[Text Word] OR "high-grade glioma"[Text Word])) AND (bevacizumab[Text Word] OR Avastin[Text Word])

The complete search strategies for all databases are provided in Supplementary File 2.

Inclusion and Exclusion Criteria

Studies were eligible for inclusion if they involved adult patients (≥18 years) with histologically confirmed glioblastoma, including both newly diagnosed and resectable cases. The intervention of interest was bevacizumab (BEV), administered either as monotherapy, as neoadjuvant therapy, or in combination with other modalities such as temozolomide (TMZ) and radiotherapy (RT). Comparators included any standard-of-care treatment not involving bevacizumab, such as temozolomide alone, chemoradiotherapy (RT+TMZ), or placebo. Eligible studies were required to report at least one relevant outcome. Primary efficacy outcomes included overall survival (OS), progression-free survival (PFS), and hazard ratios (HR) for survival with 95% confidence intervals (CI). Secondary and exploratory outcomes included median OS and PFS, overall response rates, and biomarker expression changes such as microvessel density (MVD), MIB-1 index, and Nestin-positive cells. Eligible study designs comprised randomized controlled trials (RCTs), non-randomized clinical trials, and cohort studies (prospective or retrospective) published in peer-reviewed journals.

Studies were excluded if they involved pediatric patients (<18 years old) or patients with brain tumor types other than histologically confirmed glioblastoma, such as astrocytoma, oligodendroglioma, or brain stem glioma, or if the diagnosis of glioblastoma was not confirmed. Also, studies including patients with unresectable or recurrent high-grade glioma was excluded. Studies were also excluded if the intervention did not involve bevacizumab (BEV) in any form (monotherapy, neoadjuvant, or combination therapy). For the specific analysis of neoadjuvant

efficacy, studies in which bevacizumab was not administered in a preoperative setting were excluded. In terms of outcomes, studies that did not report any of the predefined primary or secondary outcomes (overall survival, progression-free survival, hazard ratios, median values, overall response rates, biomarker data, or adverse events) or those with non-extractable or unusable data were excluded. With respect to study design, we excluded non-primary research publications (such as reviews, editorials, letters, and conference abstracts without sufficient data), preclinical studies including animal models or in-vitro experiments, duplicate reports of the same study population, and case series.

Screening and Study Selection

A comprehensive search of the aforementioned databases yielded a total of 9358 records. After removing duplicate entries, as well as reviews, books, speeches, conference abstracts, editorials, commentaries, and expert opinions, 3,988 studies remained for title and abstract screening. The title and abstract screening phase was independently performed by two reviewers (FT, MB) using the Rayyan platform to facilitate blinded and efficient screening, based on predefined PICOS-based inclusion and exclusion criteria. Any disagreements were resolved through discussion, and unresolved conflicts were adjudicated by a third reviewer (FF). Full texts of potentially eligible studies were then retrieved for detailed assessment. The full-text screening was independently conducted by two other reviewers (AV, FS), with any conflicts again resolved by consensus and, when needed, by arbitration from the third reviewer (FF).

The study selection process is summarized in Figure 1, which presents the PRISMA flowchart.

Data Extraction

Data from all included studies were extracted completely independently and in duplicate by two reviewers (FS and AV) using a predesigned standardized form. Any discrepancies between the two reviewers were resolved through discussion, and, when necessary, by consultation with a third reviewer (FF) to reach consensus. The extracted variables included: Study characteristics: authors, year of publication, country, and study design; Population details: sample size, patient demographics, tumor status (newly diagnosed); Interventions and comparators: bevacizumab regimens (monotherapy, neoadjuvant, or combination therapy) and control arms (e.g., temozolomide alone or standard chemoradiotherapy); Outcomes: overall survival (OS), progression-free survival (PFS), hazard ratios (HR), response rates, adverse events, and biological markers where available and Funding sources and sponsorship when reported.

This structured approach ensured that all relevant clinical and methodological data were accurately captured for qualitative synthesis and meta-analysis.

Quality Assessment

The methodological quality of all included studies was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklists, appropriate for each study design. The quality assessment was performed independently by two reviewers (FT and MB). The following JBI checklists were applied based on the study design:1. Cohort Studies (The JBI checklist for cohort studies evaluated: Similarity of groups at baseline, Appropriateness of recruitment methods, Measurement validity and reliability of exposures, Identification and adjustment of confounding factors, Completeness and adequacy of follow-up, Appropriate statistical analysis)(18). 2. Non-Randomized Clinical Trials (Quasi-Experimental Studies)(The quality assessment focused on: Clear cause-and-effect relationship, Similarity of participants in comparison groups, Consistency and reliability of outcome measurements, Management and reporting of confounding factors, Appropriateness of statistical analysis, Completeness of follow-up(19). 3. Randomized Controlled Trials (RCTs)(The RCT checklist evaluated: Randomization method and allocation concealment, Similarity of groups at baseline, Blinding of participants, personnel, and outcome assessors, Completeness of follow-up and intention-to-treat analysis, Validity and reliability of outcome measures, Appropriateness of statistical analysis)(19). 4. Economic Evaluation Studies(For studies reporting cost-effectiveness or economic outcomes, the JBI Economic Evaluation Checklist assessed: Clear definition of perspective and comparators, Transparency of cost identification and measurement, Validity and reliability of outcome measurement, Appropriateness of cost-effectiveness analysis, Consideration of uncertainty and sensitivity analyses (24).

All studies were evaluated using four possible responses for each checklist item: "Yes," "No," "Unclear," or "Not applicable." These structured responses allowed for a transparent assessment of methodological quality and facilitated consistent evaluation across different study designs.

Data Synthesis and Statistical Analysis

For quantitative synthesis, effect sizes for time-to-event outcomes (OS and PFS) were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). For each eligible study, the natural logarithm of the HR (logHR) and its standard error (SE) were calculated from reported HRs and 95% CIs, or reconstructed from Kaplan–Meier curves when necessary (25). The meta-analysis was conducted using the meta package in R (R Foundation for Statistical Computing, Vienna, Austria). Pooled estimates were obtained with a random-effects model to account for between-study variability, with the restricted maximum-likelihood (REML) method used to estimate τ^2 (between-study variance). Between-study heterogeneity was assessed using Cochran's Q test ($p<0.10$ indicating significance) and quantified by the I^2 statistic. Pooled logHRs were

exponentiated back to HRs for ease of interpretation. Publication bias was evaluated using funnel plots. All statistical tests were two-sided, with p < 0.05 considered statistically.

Certainty of evidence (GRADE approach)

We applied the GRADE framework to rate the certainty of evidence for each primary and secondary outcome across studies. Domains considered were:

1. Risk of bias (study limitations)

2. Inconsistency (heterogeneity in effect estimates)

3. Indirectness (applicability to the research question)

4. Imprecision (width of 95% CIs, sample size)

5. Publication bias

Two reviewers (FT, FF) independently performed GRADE rating; discrepancies were resolved by consensus.

Summary rating:

- OS: Low certainty (downgraded for risk of bias, imprecision, possible publication bias)

- PFS: Low certainty (same reasons as OS; magnitude of effect non-significant)

- KPS/steroid-sparing: Low certainty (non-blinded, subjective outcome, small sample sizes)

- MRI/biomarker: Very low certainty (surrogate outcomes, small exploratory studies)

- Adverse events: Low certainty (under-reporting in non-RCTs, imprecision)

A summary of these ratings is presented in Table 1.

Certainty of evidence (GRADE) (Table 1)

Outcome	No. of studies (participants)	Study design	Certainty	Key reasons for rating down
Overall survival (OS)	4 (n=751)	1–2 RCTs + non-RCTs	⬜⬜⬜⬜ Low	Risk of bias due to non-randomized designs; imprecision (wide CI crossing 1.0);

				possible publication bias
Progression-free survival (PFS)	4 (n=751)	1–2 RCTs + non-RCTs	⬜⬜⬜⬜ Low	Same as OS; no significant effect for pooled HR; CI wide
Functional status (KPS, steroid sparing)	≥6 studies	Mostly prospective cohorts	⬜⬜⬜⬜ Low	Lack of blinding; small sample sizes; subjective measures
Radiological response	4–5 studies	Mixed	⬜⬜⬜⬜ Very low	Surrogate endpoints; high indirectness; small samples
Histopathological / biomarkers	4–5 studies	Mixed	⬜⬜⬜⬜ Very low	Surrogate; high risk of bias; exploratory
Adverse events	5–6 studies	Mixed	⬜⬜⬜⬜ Low	Under-reporting in non-RCT; imprecision

The detailed Summary of Findings table is provided in *Supplementary 3*

Identification of studies via databases and registers

Identification

Records identified from*:
    PubMed (n = 691)
    Scopus (n =3412)
    Web of Science (n=2018)
    Embase (n=2981)
    Cochrane (n=256)

Records removed *before screening*:
    Duplicate records removed (n =781)
    Records reviews, Book, speeches, Conference abstracts only, Editorials, commentaries , expert opinions (n = 4589)

Records screened
(n =3988)

Records excluded**
(n =3928)
Reason:
1. Studies focused on tumors other than glioblastoma
2. evaluating treatments without bevacizumab
3. using bevacizumab only in adjuvant
4. using bevacizumab only

Figure 1. PRISMA 2020 flow diagram

.The characteristics and outcomes of studies evaluating neoadjuvant bevacizumab in glioblastoma are summarized in Table 2.

Study	Country	type of study	Age (years)	Sex	BEV neoadjuvan therapy dosage	Time to surgery	PSF (Months)	OS (Months)	HR	Risk of bias assessment
Chen et al., 2020 (17)	China	Cohort	Mean: 62 Range: 36–75	M:55(%54), F:47(%46)	BEV:10 mg/kg		Median PFS, months (95% CI):[1.Bev+TMZ: 4.8 (4.0-5.6)] AND [2. TMZ:2.2 (2.0-2.5)]	10.6 (6.9–14.3) vs 7.7 (5.4–10.0)	0.74	Low
Yamamoto et al. 2017 (20)	Japan	Clinical trials	Mean: 60.9 Range: 41_80	F:5 , M:10	one to three courses of pre-operative Bev at a	21-36 day after neoadjuvant therapy	Median SPD ↓43% (−8% to −61%)	10–26	-	Moderate

Study	Country	Study type	Age	Sex	Dose	Timing	PFS	OS	HR	Risk of bias
					dose of 10 mg/kg,					
Suzuki et al.,2023 (21)	Japan	Non-Randomized clinical trial	BEV neoadjuvant group: n=3, 69.7 (65_78) AND non-neoadjuvant:[n =4, 59.8,(32_76)]	BEV neoadjuvant group:[1F,2M] AND non-neoadjuvant:[1F, 3M]	2 courses of Bev(10mg/kg)	at least 5 weeks after neo-Bev	9.3	20.3	-	low
Chinot et al., 2016(12)		RCT	BEV neoadjuvant group: [n=458, 57.0 (20 –84)] And non-neoadjuvant: [n=463, 56.0 (18–79)]	BEV neoadjuvant group :[M=282 (%62)] AND non-neoadjuvant:[M=2 98 (%64)]	BEV:10 mg/kg on day 0		Group 1 (no post-PD therapy, n=225): PFS ↑ 3.6 mo (HR 0.62, 95% CI 0.46–0.84, p=0.0016). OS ↑ 3.6 mo (HR 0.67, 95% CI 0.49–0.91, p=0.0102).	Group 2 (with salvage therapy, n=696): PFS ↑ 5.2 mo (HR 0.61, 95% CI 0.51–0.71, p<0.0001); OS no significant difference (HR 0.88, 95% CI 0.73–1.05).	0.67	Low
Iwauchi et al.,2024 (22)	Japan		non-neoadjuvant: 56.8 and Bev neoadjuvant: 66.9	[1. non-neoadjuvant:M: 9 (%77.0)/F:4 (23.0)] AND [2.Bev neoadjuvant: M 12 (75.0)/F 4 (25.0)]	BEV:10 mg/kg on day 0	3-4 weeks after Neoadjuvant therapy	9/53	16/4	0.64	low
Molina et al., 2016(23)	Spain	Cohort on RCT	Mean: 64 Range: 36- 74	M: 21 (52.50%) F: 19 (47.50%)	-		4/8	10/6	2.1	Low
Rodriguez et al.,2019 (26)		cohort			-					Low
Takei et al.,2022 (27)	Japan	Clinical trials	Mean: 65.6 Range: 50–78	F:1 , M:8	BEV:10 mg/kg	3-4 weeks after Neoadjuvant therapy	9/8	16/6		Low
Tamura et al., 2019 (28)	Japan	clinical trial			BEV:10 mg/kg	21-36 day after neoadjuvant therapy	9/8	16/6		low
Tanaka et al., 2024 (13)	Japan	RCT/2nd trial	Mean: 62.2 Range: 36–74	F:6(%40), M:9(%60)	BEV:10 mg/kg	21_30 day	9.5	16.5 2-year OS rate = 20%		low

Table 2. summary of studies assessing neoadjuvant bevacizumab in patients with glioblastoma.

Result

Neoadjuvant bevacizumab treatment protocol

As summarized in Table 3, across all included studies, bevacizumab was consistently administered at 10 mg/kg in the neoadjuvant setting. However, substantial protocol variability

emerged in the number of preoperative cycles, the nature of concomitant chemoradiotherapy, and the interval between final BEV infusion and surgery.

- Chen et al., 2020 (17): BEV (days 1 & 15) combined with oral temozolomide (TMZ, 85 mg/m²/day, days 1–21) for two 28-day cycles before surgery. Postoperatively, BEV was permitted for up to six maintenance cycles.

- Yamamoto et al., 2017 (20): One to three BEV doses preoperatively; surgery performed 21–36 days after the final infusion.

- Suzuki et al., 2023 (21): Two BEV doses followed by RT (40–60 Gy) and continuous TMZ (75 mg/m², 42 days), with surgery ≥ 5 weeks later; maintenance BEV+TMZ thereafter.

- Takei et al., 2022 (27): Single-dose BEV; surgery in 3–4 weeks; BEV+TMZ resumed at recurrence and continued (mean = 16.1 cycles).

- Tanaka et al., 2024 (13): Single BEV+TMZ course; surgery in 3–4 weeks; no postoperative BEV maintenance.

- Chinot et al., 2016 (12): BEV started preoperatively and continued as long-term maintenance.

These differences—particularly in timing to surgery and whether BEV continued postoperatively or at recurrence—created significant *clinical* heterogeneity, despite similar dosing.

Table 3 – Neoadjuvant bevacizumab protocols

Study (Year)	BEV Dose	Cycles	Concomitant Therapy	Surgery Interval from bevacizumab	Maintenance BEV	References
Chen, 2020	10 mg/kg *	2	TMZ	Post-cycle	≤ 6 cycles	(17)
Yamamoto, 2017	*	1-3	none	21–36 days	None	(20)
Suzuki, 2023	*	2	RT + TMZ	≥ 5 weeks	BEV+TMZ	(21)
Takei, 2022	*	1	None; TMZ+BEV at recurrence	3–4 weeks	Yes in recurrence	(27)
Tanaka, 2024	*	1	TMZ	3–4 weeks	No	(13)
Chinot, 2016	*	NR	None	NR	Yes	(12)

*: same dose / NR: not reported

/ BEV: bevacizumab / TMZ: temozolomide/ RT: radiotherapy/

Primary Outcomes: Overall Survival (OS) and Progression-Free Survival (PFS)

As presented in Table 4, meta-analysis of four eligible studies (n = 751) demonstrated no statistically significant pooled effect of neoadjuvant bevacizumab (BEV) on either PFS or OS:

- PFS: HR = 0.7175 (95% CI: 0.4224–1.2188), p = 0.2195, I^2 = 0%

- OS: HR = 0.7249 (95% CI: 0.4211–1.2481), p = 0.2459, I^2 = 0%

The very low I^2 indicates minimal statistical heterogeneity, whereas clinical heterogeneity was substantial due to differences in dosing schedules, combination with temozolomide ± preoperative radiotherapy, and timing of surgery.

In RCTs (Molina 2016 (23), Chen 2020 (17), Chinot 2016 (12)), numerical improvements in PFS occurred but did not reach significance in pooled analysis. In smaller single-arm trials (Tanaka 2024 (13), Takei 2022 (27)), median OS was ≈ 16 months and median PFS ≈ 9 months, but absence of control arms limits conclusions.

Sensitivity and publication bias: Funnel plots suggested no strong asymmetry. Egger's test was not applied (< 10 studies/outcome). Leave-one-out analyses showed no excessive influence by any single study; pooled HRs changed by < 5% in all iterations.

Table 4 – Pooled survival outcomes

Outcome	No. studies (n patients)	Pooled HR (95% CI)	p-value	I^2 (%)	Certainty (GRADE)	References
PFS	4 (751)	0.7175 (0.4224–1.2188)	0.2195	0	Low	(17, 23)
OS	4 (751)	0.7249 (0.4211–1.2481)	0.2459	0	Low	*

*: same reference / PFS: Progression-Free Survival / OS: Overall Survival

Neurological and Functional Outcomes

As summarized in Table 5, neoadjuvant BEV frequently preserved or improved neurological and functional outcomes.

- Tanaka et al., 2024 (13): KPS rose from 83.3 ± 7.8 to 94.7 ± 4.5 (p < 0.0024); Mini-Mental State Examination (MMSE) from 21.3 to 27.5 (p < 0.0026).

- Yamamoto et al., 2017 (22): KPS improved from 50–80 to 80–100 in all patients (n=9).

- Chinot et al., 2016 (12): Median KPS ≥ 70 was 7 months with BEV vs 3 months placebo; corticosteroid discontinuation 70.6% vs 47.5%.

Table 5 – Functional outcome measures

Study	Patients number	Pre-KPS%	Post-KPS%	Other Functional Gains	References
Tanaka, 2024	15	83.3	94.7	MMSE ↑ from 21.3 to 27.5	(13)
Yamamoto, 2017	9	50-80	80–100	ADL improvement	(20)
Chinot, 2016	124	≥ 70 (3 mo)	≥ 70 (7 mo)	Steroid-sparing effect	(12)

MMSE: Mini-Mental State Examination/ ADL : Activities of Daily Living

Radiological Outcomes

As detailed in Table 6, radiological assessments consistently demonstrated reductions in tumor burden and peritumoral edema with neoadjuvant BEV.

- Tanaka, 2024 (13) : Mean reduction: −36.2% (T1CE), −54.0% (FLAIR); larger T1CE reductions trended toward better OS.

- Takei, 2022 (27): Median reduction: −38% (T1Gd) and −54% (FLAIR).

- Suzuki, 2023 (21): FMISO-PET: HV ↓ significantly (p = 0.03), but changes transient.

- Rodriguez, 2019 (26): Multimodal MRI advanced detection of progression (~6% earlier).

- Molina, 2016 (23): Lower pre-treatment necrotic volumes predicted OS benefit in BEV arm.

Table 6 – Radiological changes with neoadjuvant BEV

Study	Imaging Modality	Main Findings	References
Tanaka, 2024	MRI T1CE/FLAIR	Tumor vol ↓36.2% / edema ↓54.0%	(13)
Takei, 2022	MRI T1Gd/FLAIR	Tumor vol ↓38% / edema ↓54%	(27)
Suzuki, 2023	FMISO-PET	HV ↓ (p=0.03) – transient effect	(21)
Rodriguez, 2019	MRI multimodal	↑ detection speed of progression	(26)
Molina, 2016	MRI volumetry	Low necrosis → ↑ OS benefit	(23)

MRI :Magnetic Resonance Imaging /T1CE :T1-weighted Contrast-Enhanced sequence /FLAIR :Fluid-Attenuated Inversion Recovery /T1Gd :T1-weighted Gadolinium-enhanced sequence/ FMISO-PET :^18F-fluoromisonidazole Positron Emission Tomography/ HV :Hypoxic Volume/ OS :Overall Survival

Histopathological and Molecular Findings

As summarized in Table 7, BEV induced marked but often transient molecular changes:

- Suzuki, 2023 (21): ↓ CA9, PD-L1, CD163; ↓ CD34; modulated FOXM1.

- Takei, 2022 (27): Pseudo-papillary structures at recurrence; differential CA9/HIF-1α expression.

- Yamamoto, 2017 (20): ↓ MVD, ↓ nestin+ stem-like cells; hypoxia rebounded at recurrence; ↑ VEGF/VEGFR1.

- Tamura, 2019 (28): ↓ PD-L1, Foxp3+, PD-1+; ↑ CD8+/CD3+ T-cell infiltration.

- Chen, 2020 (17): ↓ CD34, ERG; vascular remodeling.

Table 7 − Histopathological/molecular effect

Study	Main Findings	References
Suzuki, 2023	↓ CA9, PD-L1, CD34; temp. hypoxia/stemness modulation	(21)
Takei, 2022	Pseudo-papillary structures post-BEV; CA9/HIF-1α spatial variation	(27)
Yamamoto, 2017	↓ MVD, ↓ stemness; hypoxia rebound at recurrence	(20)
Tamura, 2019	↓ PD-L1/Tregs; ↑ cytotoxic T-cells	(28)
Chen, 2020	↓ vascular density/ERG; vessel remodeling	(17)

CA9 :Carbonic Anhydrase IX (hypoxia-associated enzyme) /PD-L1 :Programmed Death-Ligand 1 (immune checkpoint ligand) /CD34 :Cluster of Differentiation 34 (endothelial cell marker)/HV :Hypoxic Volume /HIF-1α : Hypoxia-Inducible Factor 1-alpha (transcription factor induced by low oxygen) /MVD :Microvessel Density /FOXM1 : Forkhead Box M1 (transcription factor linked to cell proliferation and stemness)/Tregs :Regulatory T cells (immunosuppressive lymphocyte subset)/PD-1:Programmed Cell Death Protein 1 (immune checkpoint receptor) / CD3:Cluster of Differentiation 3 (pan-T-cell marker) /CD8 :Cluster of Differentiation 8 (cytotoxic T-cell marker) / CD163 :Cluster of Differentiation 163 (marker of M2-type macrophages) /ERG :ETS-Related Gene (endothelial transcription factor) /Nestin :Intermediate filament protein expressed in neural stem/progenitor cells /MIB-1/Ki-67 : Proliferation index antigen /VEGF :Vascular Endothelial Growth Factor /VEGFR1 :Vascular Endothelial Growth Factor Receptor 1

Safety and Adverse Events

- Tanaka, 2024 (13): No intraoperative hemorrhage; 1 wound dehiscence G3 (car-mustine-related).

- Chinot, 2016 (12): SAE: 50.8% vs 36.0% (control); G3–5 AE: 72.6% vs 63.0%.

Common: hypertension, thromboembolism, delayed wound healing.

As summarized in Table 8, Quantitative safety data were available only from Tanaka 2024 and Chinot 2016; other included studies provided either qualitative descriptions or did not report safety outcomes, limiting pooled safety analysis.

Table 8 – Safety profile

Study	SAE (%)	G3–5 AE (%)	Notable Events	References
Tanaka, 2024	NR	6.7	Wound dehiscence (CTCAE G3) with infection[c]; postoperative hematoma (likely TMZ-induced thrombocytopenia)	(13)
Chinot, 2016	50.8	72.6	Hypertension; thromboembolic events; proteinuria; delayed wound healing	(12)

SAE (%) :Serious Adverse Events /AE :Adverse Events

Cost-Effectiveness

- Chen, 2020 (21): BEV+TMZ exceeded China's willingness-to-pay threshold over 10 years; cost driven by drug price; biomarker-guided use recommended for economic viability.

7.Analysis of Progression-Free Survival (PFS) and Overall Survival (OS)

A total of four studies comprising 751 participants were included in the meta-analysis. Individual study HRs for progression-free survival (PFS) ranged from 0.62 to 1.9. For overall survival (OS), individual study HRs ranged from 0.64 to 2.1. The pooled analysis using a random-effects model showed an HR of 0.7175 (95% CI, 0.4224–1.2188, p = 0.2195) for PFS and an HR of 0.7249 (95% CI, 0.4211–1.2481, p = 0.2459) for OS. There was low heterogeneity among studies for both OS and PFS (I^2 = 0.0%). A forest plot illustrating individual study estimates and the overall pooled hazard ratio is presented in Figures 2 and 3. Despite substantial clinical heterogeneity in protocols, statistical heterogeneity was minimal (I^2=0%). This may reflect the small number of studies and wide confidence intervals, and should not be interpreted as clinical homogeneity.

Figure 2. Forest plot of Overall Survival (OS), Progression-Free Survival (PFS).

Figure 3. Funnel plot of Overall Survival (OS), Progression-Free Survival (PFS).

Discussion

Summary of Main Findings

In this systematic review and meta-analysis of 13 studies (4 eligible for quantitative survival synthesis; total $n = 751$), neoadjuvant bevacizumab (BEV, 10 mg/kg per infusion) was evaluated in newly diagnosed, surgically resectable glioblastoma. Across randomized controlled

trials (RCTs) and prospective single-arm designs, pooled hazard ratio (HR) estimates showed a numerical, non-significant trend toward benefit in both major endpoints, with minimal statistical heterogeneity:

- Progression-free survival (PFS): HR = 0.7175 (95% CI 0.4224–1.2188; p = 0.2195; I^2 = 0%) (12, 13, 17, 23)

- Overall survival (OS): HR = 0.7249 (95% CI 0.4211–1.2481; p = 0.2459; I^2 = 0%) (12, 13, 17, 23)

Median OS in smaller non-randomized trials was ≈ 16 months, with PFS ≈ 9 months (13, 27). The GRADE assessment rated the certainty of evidence as low for survival outcomes, due to risk of bias, imprecision, and possible publication bias.

Interpreting PFS–OS Divergence in Bevacizumab-Treated Glioblastoma

In the pooled analysis of four quantitative studies (n = 751), neoadjuvant BEV improved PFS (pooled HR = 0.7175, 95% CI 0.4224–1.2188) without achieving a statistically significant OS gain (HR = 0.7249, 95% CI 0.4211–1.2481) (12, 13, 17, 23). This PFS–OS divergence mirrors findings from adjuvant and recurrent GBM trials, where anti-VEGF–induced radiographic responses did not consistently translate into prolonged survival (10-12). Biological factors likely contribute, including the highly infiltrative nature of GBM that limits the cytoreductive benefit of vascular normalization, and emergence of adaptive resistance involving hypoxia and alternative angiogenic pathways (20, 21, 27, 29).The GRADE rating for both endpoints was low certainty, downgraded for study design limitations, imprecision from wide confidence intervals crossing unity, and possible publication bias.

Clinical and Functional Impact

Consistent across RCTs and prospective cohorts, BEV maintained or improved functional scores in the perioperative period (30-32). In Tanaka 2024, mean KPS rose from 83.3 to 94.7 (p < 0.0024) and MMSE from 21.3 to 27.5 (p < 0.0026) after preoperative BEV (13). Yamamoto 2017 observed increases in KPS categories (50–80 → 80–100) after one to three pre-op doses (20). Chinot 2016 reported KPS ≥ 70 preserved for 7 months with BEV vs 3 months in placebo, plus higher steroid discontinuation rates (70.6% vs 47.5%)(12).These outcomes, although subject to bias due to lack of blinding and small numbers, suggest tangible quality-of-life benefits and received a low certainty GRADE rating.

Managing Peritumoral Edema: Dexamethasone Versus Bevacizumab

Preoperative BEV induced marked edema reduction by MRI (−54% median/mean in FLAIR volume in Tanaka and Takei studies) (13, 27), which clinically obviated or minimized corticosteroid needs in several trials (12, 13, 20). Compared to dexamethasone, BEV offers a

mechanism-driven VEGF blockade reducing vascular permeability without the wide metabolic and endocrine adverse effects of chronic steroids, though cost and access differ substantially(33). GRADE certainty for steroid-sparing effects was low due to limited and non-randomized data.

The Role of Imaging in Evaluating Bevacizumab Efficacy

MRI volumetrics (T1CE, T1Gd, FLAIR) reliably detected tumor and edema shrinkage after BEV.FMISO-PET hypoxia imaging in Suzuki 2023 showed significant hypoxic volume reduction (p = 0.03) but transient effect with recurrence (21). Molina 2016 identified necrotic volume and rim heterogeneity as potential predictive biomarkers for OS benefit, but only in BEV-treated patients (23).Multimodal MRI approaches also supported earlier detection of progression (HERBY pediatric arm) (26).Radiological endpoints were graded very low certainty due to surrogate nature, indirectness, and small exploratory samples.

Histological Changes and Adaptive Responses

Histopathology confirmed transient vascular normalization ($\downarrow$CD34, $\downarrow$ERG, $\downarrow$glomeruloid vascularity), reduced hypoxia markers ($\downarrow$CA9, $\downarrow$HIF-1α), lowered stemness ($\downarrow$nestin, $\downarrow$FOXM1), and immunomodulation ($\downarrow$PD-L1, $\downarrow$Tregs/Foxp3$^+$, $\uparrow$CD8$^+$ T-cell infiltration) in the early post-BEV period(17, 20, 21, 27, 28). Recurrence specimens showed adaptive resistance features — re-expression of hypoxia markers, VEGF/VEGFR1 upregulation, and persistence of perivascular stem-like niches (20, 27, 34, 35).These dynamic changes suggest a narrow perioperative "window" of biological vulnerability. Certainty: very low (surrogate measures, exploratory analyses).

Potential Biomarkers for Predicting Bevacizumab Benefit

MRI-derived volumetrics (necrotic core size, rim heterogeneity(23)), FMISO-PET hypoxic volume changes (21), and immunohistochemical hypoxia/stemness profiles (21, 23) have emerged as potential predictors. However, none have undergone external validation, and predictive ability remains hypothesis-generating. GRADE: very low, with strong recommendation for biomarker-integrated trial designs.

Safety of Bevacizumab Administration

Across BEV arms, no intraoperative hemorrhages were reported(36); wound healing issues were infrequent (one grade 3 in Tanaka) (13). In Chinot 2016, grade 3–5 AEs occurred in 72.6% BEV vs 63% placebo, including hypertension, thromboembolic events, and delayed wound healing (12). Low certainty stems from under-reporting and limited randomized perioperative safety datasets.

Impact on Surgical Planning

Several surgical series documented improved tumor–brain margin clarity and reduced mass effect after BEV, enabling maximal safe resection and expanding eligibility for awake craniotomy (21, 23). Importantly, 5-ALA fluorescence was not impaired when surgery occurred ≥3 weeks post-BEV(23). These effects, although anecdotal, suggest an underexplored utility in operative strategy.

Cost-effectiveness Considerations

Chen 2020 found BEV + TMZ substantially exceeded willingness-to-pay thresholds due to the absence of durable OS benefit (17). Model sensitivity was driven by drug acquisition cost and PFS–OS disconnect; no neoadjuvant-specific cost-utility study exists. GRADE: low certainty (single study, non-neoadjuvant-specific economic model).

Seizure Control and Antiseizure Drug Dependence

Despite the edema-reducing mechanism and evidence from recurrent GBM suggesting reduced seizure burden with BEV (37), none of the neoadjuvant studies systematically reported seizure frequency or ASM dependence. This represents a key evidence gap.

Additional Observations:

Neoadjuvant BEV appeared to enhance surgical planning by improving tumor–brain interface visualization, facilitating safe resection and eligibility for awake craniotomy without impairing 5-ALA fluorescence (13, 38, 39). Economic analysis in Chen 2020 (17)showed incremental cost-effectiveness ratio far above willingness-to-pay thresholds, driven by absent OS gain. Seizure control(despite plausible benefit from anti-edema effects)was not systematically reported, though recurrent-GBM data suggest potential reduction (37).

Overall Interpretation:

Neoadjuvant BEV in resectable GBM provides consistent radiological and functional gains, transient biological modulation, and possible surgical facilitation, but without demonstrable long-term OS benefit. These findings support its role as a peri-operative adjunct rather than a definitive disease-modifying agent, pending validation in biomarker-enriched, protocol-standardized RCTs with integrated cost-effectiveness and patient-centred endpoints.

Limitation:

- **Heterogeneity in Intervention Protocols**

Although all included studies administered neoadjuvant bevacizumab (BEV) at 10 mg/kg, substantial clinical heterogeneity existed in the number of preoperative cycles, concomitant therapies (temozolomide ± preoperative radiotherapy), timing from final BEV infusion to surgery (ranging from 21 days to ≥ 5 weeks), and whether BEV was continued postoperatively or at recurrence(12, 13, 17, 20, 21, 23).This variability complicates cross-trial comparisons and limits the certainty of pooled outcomes.

- **Small Sample Sizes and Limited Randomized Evidence**

Of the 10 included studies, only two were RCTs;the remainder were non-randomized clinical trials or cohort studies with modest sample sizes (n often < 50). The meta-analysis for OS and PFS was based on only four studies (n = 751), reducing statistical power and increasing susceptibility to type II error.

- **Potential Selection Bias**

Non-randomized designs are prone to selection bias, especially where patient inclusion may have been influenced by clinical status, tumor location, or surgeon preference. Patients receiving BEV in neoadjuvant fashion may have differed systematically from controls in ways that favored functional preservation independent of the drug effect.

- **Incomplete and Inconsistent Reporting of Secondary Outcomes**

Functional measures (e.g., KPS, MMSE, activities of daily living) were reported in only a subset of studies ,often without standardized assessment protocols or blinding, raising the risk of observer bias. Clinical endpoints such as seizure control and antiseizure drug dependence were not systematically evaluated, despite plausible mechanistic relevance.

- **Surrogate and Exploratory Endpoints**

Radiological and histopathological changes, although consistent across studies, were surrogate markers with uncertain correlation to long-term survival. Imaging endpoints varied in acquisition protocols, segmentation thresholds, and quantification methods. Histopathological and biomarker analyses were exploratory, frequently limited to small subsets, and lacked validation.

- **Adverse Event Under-reporting**

Formal safety data were available from only two studies ;other studies offered qualitative descriptions or none at all. Given known BEV-associated risks (hypertension, thromboembolism, wound-healing delays), the inability to quantify perioperative risk across all cohorts is a significant gap.

- **Low or Very Low GRADE Certainty**

Using the GRADE framework, pooled evidence for OS, PFS, and functional status was rated as low certainty, and for radiological and biomarker endpoints as very low certainty, due to risk of bias, imprecision, indirectness, and potential publication bias (Table 4–7). This limits the strength of inferences.

- **Publication and Language Bias**

Despite a comprehensive multi-database search without language restrictions, unpublished negative studies—particularly from industry-sponsored trials—may exist, potentially inflating apparent benefits.

Future Directions

Given the above limitations and current evidence gaps, several priorities for future research are clear:

1. **Well-Powered Randomized Controlled Trials**

Large, multicenter RCTs with standardized neoadjuvant BEV protocols—fixed timing relative to surgery, defined number of cycles, and predefined criteria for postoperative continuation—are required to robustly evaluate OS, PFS, and patient-centred outcomes.

2. **Integration of Translational Endpoints**

Prospective correlation of imaging (e.g., volumetric MRI, advanced perfusion, FMISO-PET) with histopathological and molecular markers (hypoxia, stemness, immune modulation) could validate prognostic and predictive biomarkers identified in current studies.

3. **Biomarker-Driven Patient Selection**

Trials should stratify by baseline MRI necrotic volume, rim heterogeneity , hypoxic burden, and immune profile to identify responder subgroups and avoid unnecessary toxicity in non-responders.

4. **Quality-of-Life and Functional Outcomes**

Standardized, blinded KPS and neurocognitive assessments, as well as seizure frequency and steroid dependence, should be systematically collected and reported in all neoadjuvant studies.

5. **Safety and Perioperative Risk Characterization**

Uniform perioperative AE reporting, including wound-healing outcomes, thromboembolic events, and blood pressure control, must be embedded into trial designs to inform surgical safety.

6. Health Economics Analysis

Cost-effectiveness should be evaluated specifically for neoadjuvant BEV, integrating drug costs, hospitalization, functional preservation benefits, and impact on subsequent therapy costs .

7. Combination and Sequencing Strategies

Investigations into neoadjuvant BEV combined with other targeted, immunotherapeutic, or metabolic agents may overcome resistance pathways (e.g., PI3K-mediated hypoxia adaptation) observed in recurrence .

Conclusion

In summary, neoadjuvant bevacizumab in newly diagnosed, resectable glioblastoma consistently confers short-term radiographic and clinical benefits—most notably in reducing tumor volume and peritumoral edema, extending PFS, and preserving functional status—without a demonstrable OS advantage in pooled analyses. Histopathological and molecular studies confirm transient vascular normalization, hypoxia mitigation, stemness reduction, and immune activation, but adaptive resistance mechanisms emerge rapidly.

Current evidence, predominantly of low to very low certainty (GRADE), is constrained by heterogeneous protocols, small sample sizes, and incomplete outcome reporting. Routine adoption of neoadjuvant BEV outside clinical trials is not supported at present. Nevertheless, its perioperative utility—particularly for edema control, surgical facilitation, and functional preservation—warrants further investigation within rigorously designed, biomarker-integrated RCTs. Future studies should address cost-effectiveness, optimize patient selection, and incorporate patient-centred outcomes to define BEV's role in multimodal glioblastoma therapy.

Declaration of Interest

The authors declare no competing interests.

Declaration of AI Use

Artificial intelligence (AI) tools (ChatGPT) were used to improve the grammar, clarity, and language of this manuscript. The authors reviewed and approved all content, and take full responsibility for the integrity and accuracy of the work.

Acknowledgments

The authors have no acknowledgments to declare.

Funding

This research received no external funding.

Appendix and Supplementary Material

- Appendix 1. Systematic Review Protocol

- Appendix 2. Search Strategy

- Appendix 3.Certainty of evidence (GRADE approach)

- Appendix 4. Data extraction Sheets

- Appendix 5. Risk of bias Tables

- Appendix 6. Excluded studies

References:

1.   Czarnywojtek A, Borowska M, Dyrka K, Van Gool S, Sawicka-Gutaj N, Moskal J, et al. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques. Pharmacology. 2023;108(5):423-31.

2.   Hasanpour Segherlou Z, Nouri-Vaskeh M, Noroozi Guilandehi S, Baghbanzadeh A, Zand R, Baradaran B, et al. GDF-15: Diagnostic, prognostic, and therapeutic significance in glioblastoma multiforme. J Cell Physiol. 2021;236(8):5564-81.

3.   Cantrell JN, Waddle MR, Rotman M, Peterson JL, Ruiz-Garcia H, Heckman MG, et al. Progress Toward Long-Term Survivors of Glioblastoma. Mayo Clin Proc. 2019;94(7):1278-86.

4.   Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S. Survival Analysis of Glioblastoma Multiforme. Asian Pac J Cancer Prev. 2018;19(9):2613-7.

5.   Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24(1):58.

6.   Wykes V, Zisakis A, Irimia M, Ughratdar I, Sawlani V, Watts C. Importance and Evidence of Extent of Resection in Glioblastoma. J Neurol Surg A Cent Eur Neurosurg. 2021;82(1):75-86.

7.   Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.

8.   Chen H, Liang M, Min J. Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. Balkan Med J. 2021;38(1):7-12.

9.   Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017;13(28):2515-35.

10.   Lazurko C, Linder R, Pulman K, Lennox G, Feigenberg T, Fazelzad R, et al. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review. Curr Oncol. 2023;30(9):8159-71.

11.   Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024;12(3).

12.   Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, et al. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: An exploratory analysis of AVAglio. 2016;18(9):1313-8.

13.   Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto Y, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2024;166(3):557-67.

14.   Li L, Liu N, Zhang H, Tao R, Zhao S, Chen Z, et al. Potential (18)F-RGD PET/CT and DCE-MRI Imaging-Based Biomarkers for Postoperative Survival Prediction Among Patients With Newly Diagnosed Glioblastoma Treated With Bevacizumab and Chemoradiotherapy. Front Oncol. 2022;12:848266.

15.   Ezaki T, Tanaka T, Tamura R, Ohara K, Yamamoto Y, Takei J, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathol. 2024;41(2):61-72.

16.   Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, et al. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol. 2015;33(19):2166-75.

17.   Chen Z, Zhan M, Tian F, Xu T. Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma. Oncol Lett. 2020;19(1):424-30.

18.   Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Systematic reviews of etiology and risk. JBI manual for evidence synthesis. 2020;1:217-69.

19.   Barker TH, Habibi N, Aromataris E, Stone JC, Leonardi-Bee J, Sears K, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024;22(3):378-88.

20.   Yamamoto Y, Tamura R, Tanaka T, Ohara K, Tokuda Y, Miyake K, et al. "Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. ONCOTARGET. 2017;8(61):103890-9.

21.   Suzuki T, Takei J, Fukasawa N, Suzuki K, Ogawa D, Yamamoto Y, et al. (18)F-Fluoromisonidazole-Positron Emission Tomography and Immunohistochemistry Verified Tumor Oxygenation, Stemness, and Immunosupportive Microenvironment After Preoperative Neoadjuvant Bevacizumab for Newly Diagnosed Glioblastoma. World Neurosurg. 2023;175:e1364-e74.

22.   Iwauchi A, Fukasawa N, Takei J, Maeda M, Tomoto K, Teshigawara A, et al. Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma. Int J Clin Exp Pathol. 2024;17(10):346-59.

23.   Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, et al. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS One. 2016;11(8):e0161484.

24.   Gomersall JS, Jadotte YT, Xue Y, Lockwood S, Riddle D, Preda A. Conducting systematic reviews of economic evaluations. Int J Evid Based Healthc. 2015;13(3):170-8.

25.   Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

26.   Rodriguez D, Chambers T, Warmuth-Metz M, Aliaga ES, Warren D, Calmon R, et al. Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. AJNR Am J Neuroradiol. 2019;40(3):568-75.

27.   Takei J, Fukasawa N, Tanaka T, Yamamoto Y, Tamura R, Sasaki H, et al. Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas. Front Oncol. 2022;12:898614.

28.   Tamura R, Tanaka T, Ohara K, Miyake K, Morimoto Y, Yamamoto Y, et al. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci. 2019;110(2):499-508.

29.   Yang SB, Gao KD, Jiang T, Cheng SJ, Li WB. Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(34):57337-44.

30.   Sasaki S, Tsukamoto S, Ishida Y, Kobayashi Y, Inagaki Y, Mano T, et al. The Karnofsky Performance Status at Discharge Is a Prognostic Indicator of Life Expectancy in Patients With Glioblastoma. Cureus. 2024;16(8):e66226.

31.   Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncol. 2013;2(5):413-8.

32.   Gramatzki D, Roth P, Rushing EJ, Weller J, Andratschke N, Hofer S, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018;29(6):1431-6.

33.   Scharl S, Straube C, Meyer B, Schmidt-Graf F, Combs SE. [Critical consideration of the European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas]. Strahlenther Onkol. 2017;193(11):984-8.

34.   Buccarelli M, Castellani G, Ricci-Vitiani L. Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance. J Pers Med. 2022;12(10).

35.   Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, et al. Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget. 2016;7(32):52423-35.

36.   Hama Y, Sasaki T, Fukai J, Nakao N. Bevacizumab⁠associated intracerebral hemorrhage in patients with malignant glioma. Mol Clin Oncol. 2025;22(6):57.

37.   Hertler C, Seystahl K, Le Rhun E, Wirsching HG, Roth P, Weller M, et al. Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2022;24(11):2001-4.

38.   Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB, Jr., Bota DA. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. J Clin Neurosci. 2015;22(1):35-9.

39.   Beppu T, Sato Y, Yamada N, Terasaki K, Sasaki T, Sugai T, et al. Impacts on Histological Features and 11C-Methyl-L-methionine Uptake After "One-Shot" Administration with Bevacizumab Before Surgery in Newly Diagnosed Glioblastoma. Translational Oncology. 2019;12(11):1480-7.